NHS fast tracks access to Amgen’s just-approved KRAS cancer drugAmgen’s first-in-class KRAS inhibitor Lumykras has been approved in Great Britain and arrives already armed with an agreement Share XNHS fast tracks access to Amgen’s just-approved KRAS cancer drughttps://pharmaphorum.com/news/nhs-fast-tracks-access-to-amgens-just-approved-kras-cancer-drug/
2021 – UK market access prospectsWith a new year comes the opportunity to think ahead for the market access landscape for the coming Share X2021 – UK market access prospectshttps://pharmaphorum.com/views-analysis-market-access/2021-uk-market-access-prospects/
